As presented at the 2026 ASCO Genitourinary Cancers Symposium: results from a phase 1 trial of a first-in-class small-molecule inverse agonist of PPARγ in solid tumors show an acceptable safety profile and preliminary tumor activity in urothelial carcinoma.
- Matthew D. Galsky
- Charlene Mantia
- Xin Gao